Tetrahedron Letters p. 2789 - 2791 (2008)
Update date:2022-08-03
Topics:
Donohue, Sean R.
Halldin, Christer
Pike, Victor W.
Rimonabant is a high-potency cannabinoid type-1 (CB1) receptor inverse agonist that has recently been approved in the European Union as a treatment for obesity. Current methods of synthesis require several steps that have long reaction times and/or lack regioselectivity. Here we present a novel, regioselective synthesis of rimonabant though an enamine-directed 1,3-dipolar cycloaddition. In addition, we present a new and more reactive hydrazonoyl halide for the generation of the requisite nitrile imine dipole.
View Morewebsite:http://www.biet.com.cn/
Contact:+86-27-8369 8488
Address:No. 6, Building 21, China Merchants Fanwang, Sixin North Road, Hanyang District, Wuhan City, Hubei Province
Hangzhou Think Chemical Co. Ltd
website:http://www.thinkchem.com/
Contact:86-571-89986307/81956191/81956084/81956192
Address:Room 501-502, Tower E, Yuanjian Building, Yuanyang International Center, Hangzhou-310011, China
Hangzhou Pharma & Chem Co.,Ltd.
Contact:+86-571-87040515
Address:No,139Qingchun Rd
website:http://www.mascot-ie.com
Contact:86-519-85010339
Address:B-802,XingBei Building,391#,Tongjiang Middle Road New District,Changzhou,JS,China
Shanghai Hongbang Medical Technology CO.,. Ltd
Contact:13671516988 /18917636693
Address:Room1, No67 Building, Yongde Road369, Wujing Town, Minhang Districy, Shanghai CIty, China.
Doi:10.1016/S0040-4039(00)74332-2
(1991)Doi:10.1016/j.bmc.2011.10.040
(2011)Doi:10.1016/0022-328X(91)86387-6
(1991)Doi:10.1021/ol202595t
(2011)Doi:10.1021/ol202708f
(2011)Doi:10.1080/00397919108016771
(1991)